# Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

> **NCT07214207** · PHASE2 · RECRUITING · sponsor: **Ohio State University** · enrollment: 250 (estimated)

## Conditions studied

- Alcohol Use Disorder

## Interventions

- **DRUG:** Suvorexant 10 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07214207
- **Lead sponsor:** Ohio State University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-04
- **Primary completion:** 2030-09
- **Final completion:** 2030-09
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07214207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07214207, "Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07214207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*